Söndag 22 December | 05:52:30 Europe / Stockholm

Bifogade filer

Kalender

Tid*
2026-02-13 08:00 Bokslutskommuniké 2025
2025-11-14 08:30 Kvartalsrapport 2025-Q3
2025-08-29 08:30 Kvartalsrapport 2025-Q2
2025-05-15 N/A Årsstämma
2025-05-15 08:30 Kvartalsrapport 2025-Q1
2025-02-13 08:00 Bokslutskommuniké 2024
2024-11-28 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-27 - Kvartalsrapport 2024-Q1
2024-05-17 - X-dag ordinarie utdelning ELIC 0.00 SEK
2024-05-16 - Årsstämma
2024-02-20 - Extra Bolagsstämma 2024
2024-02-13 - Bokslutskommuniké 2023
2023-11-14 - Kvartalsrapport 2023-Q3
2023-08-29 - Kvartalsrapport 2023-Q2
2023-05-17 - X-dag ordinarie utdelning ELIC 0.00 SEK
2023-05-16 - Årsstämma
2023-05-16 - Kvartalsrapport 2023-Q1
2023-02-17 - Bokslutskommuniké 2022
2022-11-18 - Kvartalsrapport 2022-Q3
2022-08-22 - Kvartalsrapport 2022-Q2
2022-04-26 - Kvartalsrapport 2022-Q1
2022-03-08 - X-dag ordinarie utdelning ELIC 0.00 SEK
2022-03-07 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
2021-11-18 - Kvartalsrapport 2021-Q3
2021-08-20 - Kvartalsrapport 2021-Q2
2021-05-07 - X-dag ordinarie utdelning ELIC 0.00 SEK
2021-04-26 - Årsstämma
2021-04-14 - Kvartalsrapport 2021-Q1
2021-02-18 - Bokslutskommuniké 2020

Beskrivning

LandSverige
ListaFirst North Stockholm
SektorHälsovård
IndustriBioteknik
Elicera Therapeutics är verksamt inom läkemedelsbranschen. Bolaget är specialiserat inom forskning och utveckling inom immun-onkologi för cell- och genterapier för immunbaserad cancerbehandling. Utöver huvudverksamheten erbjuds även service och tillhörande kringtjänster. Verksamheten bedrivs med störst närvaro inom Sverige. Elicera Therapeutics har sitt huvudkontor i Göteborg.
2024-09-03 08:45:00

Gothenburg, September 3, 2024 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on CAR T-cell therapies and oncolytic viruses, armed with its proprietary and commercially available technology platform iTANK, announces that the company will participate in the following industry and investor conferences during the fall of 2024:

ISCT Europe 2024 Regional Meeting, September 4 
Elicera Therapeutics will participate in the annual conference organized by the scientific network International Society for Gene & Cell Therapy. For more information: https://www.isctglobal.org/iscteu2024/home

CICON24 (Eighth International Cancer Immunotherapy Conference), September 8 
Elicera Therapeutics' co-founder and CSO, Magnus Essand, has been invited to present iTANK and the company's development of CAR T-cell therapies. For more information: www.cancerimmunotherapyconference.org

Biostock Investor Meeting, September 12 
Elicera Therapeutics' CEO, Jamal El-Mosleh, will present the company at an investor meeting organized by Biostock. For more information: https://www.biostock.se/investing-in-life-science/

NLSDays 2024, September 18-19 
Elicera Therapeutics will participate in Nordic Life Science Days, the Nordic region's largest business conference in life science. For more information: www.nlsdays.com/about-the-event

Miltenyi Cell and Gene Therapy Summit 2024, October 8 
Elicera Therapeutics' co-founder and CSO, Magnus Essand, has been invited to present iTANK and the company's development of CAR T-cell therapies. For more information: www.miltenyibiotec.com/UN-en/about-us/conferences-and-events/miltenyi-biotec-s-cell-and-gene-therapy-days.html

BIO-EUROPE, November 4 
Elicera Therapeutics will participate in Europe's largest business conference in life science. For more information: www.informaconnect.com/bioeurope

Biostock Summit, November 19 
Elicera Therapeutics will present at the annual investor meeting organized by Biostock. The company's presentation will be published on their website.